Phase I Dose Escalation and Expansion Study of DS-7080a in Subjects With Neovascular Age-related Macular Degeneration or Diabetic Macular Edema

Trial Profile

Phase I Dose Escalation and Expansion Study of DS-7080a in Subjects With Neovascular Age-related Macular Degeneration or Diabetic Macular Edema

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs DS 7080a (Primary) ; Ranibizumab
  • Indications Age-related macular degeneration; Diabetic macular oedema
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 29 Jun 2017 Status changed from active, no longer recruiting to recruiting.
    • 20 Jun 2017 New Indication (diabetic macular edema) added, planned number of patients changed from 45 to 63, patient age altered, number of treatment arms changed from 4 to 6
    • 13 Apr 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top